List of articles with "Neurocrine"

INGREZZA® Efficacy

INGREZZA® Efficacy

Neurocrine INGREZZA Tardive Dyskinesia
Neurocrine’s INGREZZA Insights

Neurocrine’s INGREZZA Insights

USA San Diego Neurocrine INGREZZA Tardive Dyskinesia
Neurocrine's Osavampator Study

Neurocrine's Osavampator Study

United States San Diego Depression Neurocrine Osavampator
Neurocrine's CRENESSITY Data

Neurocrine's CRENESSITY Data

USA San Francisco Crenessity CAH Neurocrine
INGREZZA and Tardive Dyskinesia

INGREZZA and Tardive Dyskinesia

USA San Diego Neurocrine INGREZZA Tardive Dyskinesia
KINECT-PRO Study Insights

KINECT-PRO Study Insights

USA San Diego Neurocrine INGREZZA Tardive Dyskinesia
Neurocrine's Findings

Neurocrine's Findings

United States San Diego Neurocrine Congenital Adrenal Hyperplasia Glucocorticoids
New CMO at Neurocrine

New CMO at Neurocrine

USA San Diego CMO Neurocrine Sanjay Keswani
Insights on VMAT2 Inhibitors

Insights on VMAT2 Inhibitors

United States Houston Neurocrine INGREZZA VMAT2 Inhibitors
INGREZZA 48-Week Results

INGREZZA 48-Week Results

USA Chicago Neurocrine INGREZZA Tardive Dyskinesia
Neurocrine March Events

Neurocrine March Events

United States Boston Investor Neurocrine Biosciences
Neurocrine's $500M Buyback

Neurocrine's $500M Buyback

United States San Diego share repurchase Neurocrine INGREZZA
Neurocrine Launches Osavampator Study

Neurocrine Launches Osavampator Study

United States San Diego Neurocrine Osavampator Biosciences
Neurocrine & Takeda Deal

Neurocrine & Takeda Deal

United States San Diego Neurocrine Takeda Osavampator
Andrew Ratz Joins Neurocrine

Andrew Ratz Joins Neurocrine

United States San Diego Drug Development Neurocrine Andrew Ratz
Innovative CAH Treatment

Innovative CAH Treatment

United States San Diego Crenessity CAH Neurocrine
Crenessity™ Distribution Deal

Crenessity™ Distribution Deal

United States Pittsburgh PANTHERx Crenessity Neurocrine
Launch of CRENESSITY™

Launch of CRENESSITY™

United States San Diego Crenessity CAH Neurocrine

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.